{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:04:44Z","timestamp":1782907484480,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.jns.2007.01.053","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T11:16:59Z","timestamp":1175167019000},"page":"258-263","source":"Crossref","is-referenced-by-count":125,"title":["The cerebral vasculopathy of Fabry disease"],"prefix":"10.1016","volume":"257","author":[{"given":"David F.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"Kaneski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2007.01.053_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of angiokeratoma","volume":"18","author":"Anderson","year":"1898","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jns.2007.01.053_bib2","first-page":"361","article-title":"Diffuse angiokeratoma: report of two cases with diffuse skin changes, one with neurological symptoms and splenomegaly","volume":"33","author":"Brown","year":"1952","journal-title":"Glasgow Med J"},{"key":"10.1016\/j.jns.2007.01.053_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJM196106222642503","article-title":"Angiokeratoma corporis diffusum (Fabry's disease in two brothers)","volume":"264","author":"Bethune","year":"1961","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2007.01.053_bib4","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2007.01.053_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry's disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2007.01.053_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainresbull.2003.09.021","article-title":"White matter lesions in Fabry disease occur in \u2018prior\u2019 selectively hypometabolic and hyperperfused brain regions","volume":"62","author":"Moore","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jns.2007.01.053_bib7","first-page":"1096","article-title":"Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease","volume":"24","author":"Moore","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jns.2007.01.053_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1552-6569.2001.tb00051.x","article-title":"Selective arterial distribution of cerebral hyperperfusion in Fabry disease","volume":"11","author":"Moore","year":"2001","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.jns.2007.01.053_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000106640","article-title":"The vascular dementia of Fabry's disease","volume":"8","author":"Mendez","year":"1997","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jns.2007.01.053_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archpsyc.1973.04200030090014","article-title":"Psychosis in Fabry disease and treatment with phenoxybenzamine","volume":"29","author":"Liston","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jns.2007.01.053_bib11","first-page":"491","article-title":"The neurological complications of Anderson\u2013Fabry disease (alpha-galactosidase A deficiency)\u2014investigation of symptomatic and presymptomatic patients","volume":"75","author":"Morgan","year":"1990","journal-title":"Q J Med"},{"key":"10.1016\/j.jns.2007.01.053_bib12","first-page":"36","article-title":"Cerebrovascular manifestations in a female carrier of Fabry's disease","volume":"92","author":"Grewal","year":"1992","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.jns.2007.01.053_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2007.01.053_bib14","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.01.053_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2007.01.053_bib16","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2007.01.053_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jns.2007.01.053_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1651-2227.2002.tb03114.x","article-title":"Elevated CNS average diffusion constant in Fabry disease","volume":"91","author":"Moore","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.jns.2007.01.053_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","article-title":"Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study","volume":"20","author":"Moore","year":"2004","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.jns.2007.01.053_bib20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.STR.32.7.1559","article-title":"Enhanced endothelium-dependent vasodilation in Fabry disease","volume":"32","author":"Altarescu","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2007.01.053_bib21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-003-1133-x","article-title":"Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease","volume":"250","author":"Stemper","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2007.01.053_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jns.2007.01.053_bib23","first-page":"916","article-title":"T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease","volume":"24","author":"Takanashi","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jns.2007.01.053_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2007.01.053_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.74.4.700","article-title":"Vascular free radical release. Ex vivo and in vivo evidence for a flow-dependent endothelial mechanism","volume":"74","author":"Laurindo","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.jns.2007.01.053_bib26","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1161\/01.RES.0000101744.47866.D5","article-title":"Heparan sulfate proteoglycan is a mechanosensor on endothelial cells","volume":"93","author":"Florian","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jns.2007.01.053_bib27","first-page":"H1262","article-title":"Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite","volume":"271","author":"Wei","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jns.2007.01.053_bib28","first-page":"1","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5\u00a0years of enzyme replacement","author":"Schiffmann","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jns.2007.01.053_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency","volume":"111","author":"Bodary","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2007.01.053_bib30","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk for vasculopathic events in Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.01.053_bib31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.01.053_bib32","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2007.01.053_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A \u2014 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2007.01.053_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jns.2007.01.053_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jns.2007.01.053_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2007.01.053_bib37","unstructured":"Schiffmann R, Askari H, Timmons T, Robinson C, Benko W, Brady RO, Ries M. Weekly Enzyme replacement therapy may slow decline of renal tunction in Fabry patients on long-term biweekly dosing. J Am Soc Nephrol, in press."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T14:21:56Z","timestamp":1546957316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X07000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0022510X07000561"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2007.01.053","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}